News

MBF Bioscience Announces the Acquisition of Vidrio Technologies

MBF Bioscience, a leading provider of bioscience image analysis tools, announced that it has completed the acquisition of Vidrio Technologies. Terms of the transaction were not disclosed.

Based in Ashburn, VA, Vidrio is a fast-growing provider of software and hardware components for laser scanning and two photon microscopes.

“Vidrio Technologies builds widely loved tools for researchers who utilize two photon and laser scanning microscopes to answer some of the toughest questions in biology,” says MBF Bioscience Founder and President Jack Glaser. “They have assembled a truly special team of engineers and I am thrilled that MBF will have the opportunity to be a part of the continued development, release, and support of Vidrio’s impressive products.”

“The team at Vidrio couldn’t be more excited to be joining forces with MBF,” says Vidrio Technologies CEO Bruce Kimmel. “We have grown rapidly in recent years and MBF’s large development team will be a great resource for us as we continue to invest in the development of industry-leading tools for bioscience researchers.”

Georg Jaindl, Senior Software Engineer at Vidrio Technologies said, “Vidrio has a pipeline full of exciting new products that we can’t wait to show our customers. By joining forces with MBF, we will be able to build these tools for our customers faster and provide even more responsive technical support than our customers already receive.”

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and